BIORESTORATIVE THERAPIES INC (BRTX)
US0906556065 - Common Stock
Taking everything into account, BRTX scores 3 out of 10 in our fundamental rating. BRTX was compared to 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for BRTX as it has an excellent financial health rating, but there are worries on the profitability. BRTX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BRTX had negative earnings in the past year.
BRTX had a negative operating cash flow in the past year.
BRTX had negative earnings in each of the past 5 years.
BRTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
BRTX's Return On Assets of -114.30% is on the low side compared to the rest of the industry. BRTX is outperformed by 81.06% of its industry peers.
Looking at the Return On Equity, with a value of -124.83%, BRTX is doing worse than 60.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -114.3% | ||
| ROE | -124.83% | ||
| ROIC | N/A |
ROA(3y)-141.39%
ROA(5y)-335.97%
ROE(3y)-148.91%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for BRTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BRTX has been increased compared to 1 year ago.
The number of shares outstanding for BRTX has been increased compared to 5 years ago.
There is no outstanding debt for BRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -15.96, we must say that BRTX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BRTX (-15.96) is worse than 84.30% of its industry peers.
There is no outstanding debt for BRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -15.96 |
ROIC/WACCN/A
WACC9.27%
2.3 Liquidity
BRTX has a Current Ratio of 10.71. This indicates that BRTX is financially healthy and has no problem in meeting its short term obligations.
BRTX's Current ratio of 10.71 is amongst the best of the industry. BRTX outperforms 81.57% of its industry peers.
A Quick Ratio of 10.71 indicates that BRTX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 10.71, BRTX belongs to the best of the industry, outperforming 81.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.71 | ||
| Quick Ratio | 10.71 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 30.81% over the past year.
The Revenue has grown by 16.08% in the past year. This is quite good.
The Revenue has been growing slightly by 5.80% on average over the past years.
EPS 1Y (TTM)30.81%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q52.1%
Revenue 1Y (TTM)16.08%
Revenue growth 3Y22.15%
Revenue growth 5Y5.8%
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 32.18% on average over the next years. This is a very strong growth
Based on estimates for the next years, BRTX will show a very strong growth in Revenue. The Revenue will grow by 322.40% on average per year.
EPS Next Y39%
EPS Next 2Y23.01%
EPS Next 3Y14.99%
EPS Next 5Y32.18%
Revenue Next Year-57.75%
Revenue Next 2Y-35%
Revenue Next 3Y-24.96%
Revenue Next 5Y322.4%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BRTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BRTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as BRTX's earnings are expected to grow with 14.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.01%
EPS Next 3Y14.99%
5. Dividend
5.1 Amount
No dividends for BRTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIORESTORATIVE THERAPIES INC
NASDAQ:BRTX (5/2/2024, 7:00:01 PM)
Premarket: 1.34 -0.12 (-8.22%)1.46
+0.09 (+6.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.88M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -114.3% | ||
| ROE | -124.83% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 10.71 | ||
| Quick Ratio | 10.71 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)30.81%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y39%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)16.08%
Revenue growth 3Y22.15%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y